HOOKIPA Pharma Inc.
Claus Osterbauer has extensive work experience as a co-investor with Gateway Ventures. Claus has held roles in various companies, including Hookipa Pharma Inc., //SAIZ, Orderlion, Talkie.ai, VitreaLab, Fairown, mediaire, timeBro GmbH, tripmakery.com, and Swarm Analytics. In these roles, they have contributed to the growth and development of these companies through their investment expertise.
Claus Osterbauer obtained a Master of Laws (LLM) degree in Investment Banking, Katallaktik, and Kapitalmarktrecht from the Frankfurt School of Finance & Management from 2009 to 2011. Claus then pursued a Master of Arts (M.A.) degree in Quantitative Finance at Uniwersytet Ekonomiczny w Katowicach and at Fachhochschule des BFI Wien from 2011 to 2014. Prior to that, Claus earned a Master of Science (M.Sc.) in Wirtschaftswissenschaften from Fachhochschule Salzburg from 2003 to 2007. Additionally, they have obtained various certifications, including Certified IFRS Accountant, Certified Project Manager, and Manager für Werbung und Marktkommunikation.
This person is not in any offices
HOOKIPA Pharma Inc.
At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.